PCI Pharma Services, an integrated global contract development and manufacturing organization (CDMO), has announced a series of major infrastructure investments intended to deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize U.S. supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s U.S. and European operations, reinforcing ...